Immunomedics Revenue and Competitors

Location

$30M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Immunomedics's estimated annual revenue is currently $34.6M per year.(i)
  • Immunomedics received $125.0M in venture funding in May 2017.
  • Immunomedics's estimated revenue per employee is $288,042
  • Immunomedics's total funding is $30M.

Employee Data

  • Immunomedics has 120 Employees.(i)
  • Immunomedics grew their employee count by -8% last year.

Immunomedics's People

NameTitleEmail/Phone
1
Associate VP, Process Development and ManufacturingReveal Email/Phone
2
ControllerReveal Email/Phone
3
Director and Head Patient Experience and AdvocacyReveal Email/Phone
4
Director Process DevelopmentReveal Email/Phone
5
Exec. Director, Head ITReveal Email/Phone
6
Senior Director, Pre-Clinical DevelopmentReveal Email/Phone
7
Chief Technology OfficerReveal Email/Phone
8
Director, Clinical Digital SolutionsReveal Email/Phone
9
Chief Quality OfficerReveal Email/Phone
10
CFO & Chief Business OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.5M55-21%N/AN/A
#2
$0.2M10%N/AN/A
#3
$8.5M55-29%N/AN/A
#4
$108.5M5002%N/AN/A
#5
$0.8M50%N/AN/A
#6
$0.6M40%N/AN/A
#7
$14.7M68-23%$206.4MN/A
#8
$492.2M1503-15%$568MN/A
#9
$1.1M7-42%N/AN/A
#10
$4.5M290%N/AN/A
Add Company

What Is Immunomedics?

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.

keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power

$30M

Total Funding

120

Number of Employees

$34.6M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Immunomedics News

2022-04-20 - Gilead Takes $2.7 Billion Writedown; Covid Drug Tops ...

Gilead raised eyebrows in 2020 when it agreed to buy Immunomedics for about $21 billion, a substantial premium for a company that was...

2022-04-13 - Gilead's Immunomedics floats $4M to put ASCO data fiasco to ...

Under a proposed settlement, Gilead Sciences' Immunomedics would shell out $4 million to resolve a lawsuit alleging it violated securities laws...

2022-04-06 - Immunomedics Investors Seek First Nod for $4 Million ...

Immunomedics Inc. investors who say the company misled them about cancer drug data presentations asked a federal judge in New Jersey for...

2019-09-12 - Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in ...

Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid ...

2019-09-12 - Immunomedics to Host Investor Event and Webcast on ...

12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.7M1375%N/A
#2
$35M14026%N/A
#3
$60.7M335-2%N/A
#4
$112.1M427-2%N/A
#5
$135.4M53910%N/A

Immunomedics Funding

DateAmountRoundLead InvestorsReference
2004-01-15$10.0MnotesArticle
2005-04-28$36.7MUndisclosedMultipleArticle
2014-05-05$30.2MUndisclosedArticle
2015-02-09$96.4MUndisclosedGoldman, Sachs & Co.Article
2017-05-08$125.0MUndisclosedArticle